drugset / Trial / NCT07523282
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Phase 1
Not yet recruiting
12 enrolled
Shenzhen MagicRNA Biotechnology Co., Ltd
The First Affiliated Hospital of University of Science and Technology of China · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Timeline
- Start
- 2026-04-28
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HN2302 | Cell therapy | — | — |